Hereditary cancer panel testing challenges and solutions for the latinx community: costs, access, and variants

Michael P Douglas1, Grace A Lin2,3,4, Julia R Trosman2,5

  • 1UCSF Center for Translational and Policy Research On Personalized Medicine (TRANSPERS), Department of Clinical Pharmacy, University of California San Francisco, 490 Illinois Street, 3rd Floor, Box 0613, San Francisco, CA, 94143, USA. Michael.Douglas@ucsf.edu.

Insights

Financial assistance programs reduce hereditary cancer panel (HCP) testing costs for Latinx individuals. However, challenges remain regarding program sustainability, out-of-pocket expenses, and cascade testing access for families.

Area of Science:

  • Genetics and Genomics
  • Public Health
  • Health Disparities

Background:

  • Hereditary breast and ovarian cancers (HBOCs) disproportionately affect the Latinx population.
  • Multi-gene hereditary cancer panels (HCPs) are recommended for risk assessment.
  • Limited understanding exists regarding financial barriers to HCP testing in the Latinx community.

Purpose of the Study:

  • To identify challenges and propose solutions for facilitating HCP testing in the Latinx population.
  • To explore the impact of payer reimbursement and out-of-pocket costs on HCP utilization.

Main Methods:

  • Conducted semi-structured interviews with healthcare providers (genetic counselors, oncologists, nurse practitioners) at safety-net institutions.
  • Utilized deductive thematic analysis to identify key themes related to HCP testing barriers and solutions.
  • Focused on providers serving the Latinx population in the San Francisco Bay Area.

Main Results:

  • Laboratory patient assistance programs significantly reduce upfront financial barriers to HCP testing.
  • Potential challenges include the long-term sustainability of low-cost testing, patient out-of-pocket expenses, and access to cascade testing for relatives.
  • Pathogenic variants specific to the Latinx population require consideration in panel inclusivity.

Conclusions:

  • While financial assistance mitigates some barriers, other factors impede equitable HCP testing access for Latinx individuals.
  • Addressing sustainability of assistance programs, out-of-pocket costs, and cascade testing is crucial.
  • Ensuring comprehensive testing panels that include Latinx-specific variants is essential for improving care.